Cargando…

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts

BACKGROUND: Osteoprotegerin (OPG) has been reported to prevent bone resorption by inhibiting the formation, function, and survival of osteoclasts in a variety of animal models. However, the effects of OPG on bone metabolism in avian species have not been described. The objective of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Lele, Hou, Jiafa, Yao, Jing, Zhou, Zhenlei
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076242/ https://www.ncbi.nlm.nih.gov/pubmed/21435269 http://dx.doi.org/10.1186/1751-0147-53-21

Ejemplares similares

Biosafety, and improvement of osteoporosis in cage layers through using chOPG protein
por: Hou, Lele, et al.
Publicado: (2020)

The construction of the eukaryotic expression plasmid pcDNA3.1/azurin and the increased apoptosis of U2OS cells transfected with it
por: Ye, Zhaoming, et al.
Publicado: (2007)

In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression
por: Chen, Rong-Yi, et al.
Publicado: (2010)

Protein Expression of Mesenchymal Stem Cells after Transfection of pcDNA3.1(−)-hVEGF(165) by Ultrasound-Targeted Microbubble Destruction
por: Pu, Zhaoxia, et al.
Publicado: (2011)

Fabrication and Characterization of pcDNA3.1(+) Location within Chitosan/Nanoparticles Complexes for Enhanced Gene Delivery
por: Piri-Gharaghie, Tohid, et al.
Publicado: (2022)

Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010)

Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications
por: Bjerre, Mette
Publicado: (2013)

HSVtk/GCV system on hepatoma carcinoma cells: Construction of the plasmid pcDNA3.1-pAFP-TK and targeted killing effect
por: Li, Yong-Fang, et al.
Publicado: (2017)

Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease
por: Bolon, B, et al.
Publicado: (2001)

Immunogenic properties of empty pcDNA3 plasmid against zoonotic cutaneous leishmaniasis in mice
por: Montakhab-Yeganeh, Hossein, et al.
Publicado: (2022)

Designing and Construction Pcdna3.1 Vector Encoding Cfp10 Gene of Mycobacterium tuberculosis
por: Baghani, Akram, et al.
Publicado: (2015)

The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro
por: Zhu, Jiaqiao, et al.
Publicado: (2023)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
por: Wang, Yan, et al.
Publicado: (2011)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
por: Eid, Riham, et al.
Publicado: (2023)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Osteoprotegerin Gene (OPG) Polymorphisms Associated with Peri-Implantitis Susceptibility in a Chinese Han Population
por: Zhou, Jian, et al.
Publicado: (2016)

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021)

Expression of a chimerical pcDNA encoding influenza virus M2 protein and HSP70 gene in eukaryotic cell lines
por: Fotouhi, F, et al.
Publicado: (2011)

Effects of corticosterone on the metabolic activity of cultured chicken chondrocytes
por: Zhang, Hua, et al.
Publicado: (2015)

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
por: Zauli, Giorgio, et al.
Publicado: (2008)

The Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts
por: Xu, Tong, et al.
Publicado: (2016)

Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway
por: Liu, Wei, et al.
Publicado: (2015)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
por: Reid, Penny E, et al.
Publicado: (2009)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
por: Tariq, Saba, et al.
Publicado: (2022)

A protocol for custom CRISPR Cas9 donor vector construction to truncate genes in mammalian cells using pcDNA3 backbone
por: Vazquez, Neftali, et al.
Publicado: (2018)

Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone
por: Wang, Baoli, et al.
Publicado: (2015)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Correction to: A protocol for custom CRISPR Cas9 donor vector construction to truncate genes in mammalian cells using pcDNA3 backbone
por: Vazquez, Neftali, et al.
Publicado: (2019)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Study of the incidence of osteoporosis in patients with Sjögren’s syndrome (pSS) and investigation of activation of the RANKL /RANK and osteoprotegerin (OPG) system
por: Skarlis, Charalampos, et al.
Publicado: (2018)

Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions
por: Fu, Ying-Xiao, et al.
Publicado: (2013)

Involvement of the Ca(2+) signaling pathway in osteoprotegerin inhibition of osteoclast differentiation and maturation
por: Fu, Yingxiao, et al.
Publicado: (2015)

Effect of Bitter Compounds on the Expression of Bitter Taste Receptor T2R7 Downstream Signaling Effectors in cT2R7/pDisplay-Gα16/gust44/pcDNA3.1 (+) Cells
por: Su, Yuan, et al.
Publicado: (2019)

The genetic association between osteoprotegerin (OPG) gene polymorphisms and bone mineral density (BMD) in postmenopausal women: A meta-analysis
por: Peng, Yuqin, et al.
Publicado: (2018)

Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis
por: Goswami, Sudeshna, et al.
Publicado: (2016)

Abstract: Osteoprotegerin-Mediated Osteoclast Inhibition Is Augmented on Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials
por: Lee, Justine C., et al.
Publicado: (2018)

The ATF3–OPG Axis Contributes to Bone Formation by Regulating the Differentiation of Osteoclasts, Osteoblasts, and Adipocytes
por: Kim, Jung Ha, et al.
Publicado: (2022)

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2013)

The genetic association between osteoprotegerin (OPG) gene polymorphisms and bone mineral density (BMD) in postmenopausal women: A meta-analysis: Erratum
Publicado: (2019)

Osteoprotegerin (OPG) Promotes Recruitment of Endothelial Progenitor Cells (EPCs) via CXCR4 Signaling Pathway to Improve Bone Defect Repair
por: Zhang, Rongfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2eppheritmkbigbu4jj18r9s15